nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
|
Bogani, G. |
|
|
35 |
5 |
p. 414-428 |
artikel |
2 |
Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’
|
Burotto, M. |
|
|
35 |
5 |
p. 482 |
artikel |
3 |
Corrigendum to “Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child”
|
Abelman, R. |
|
|
35 |
5 |
p. 481 |
artikel |
4 |
Editorial Board
|
|
|
|
35 |
5 |
p. iii |
artikel |
5 |
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522☆
|
Pusztai, L. |
|
|
35 |
5 |
p. 429-436 |
artikel |
6 |
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
|
Sangro, B. |
|
|
35 |
5 |
p. 448-457 |
artikel |
7 |
Importance of pain management in cancer patients and survivors
|
Bhatt, K. |
|
|
35 |
5 |
p. 473-474 |
artikel |
8 |
New ADCs bring new questions in EGFR NSCLC and beyond
|
Scott, S. |
|
|
35 |
5 |
p. 412-413 |
artikel |
9 |
Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors
|
Belli, C. |
|
|
35 |
5 |
p. 478-480 |
artikel |
10 |
Reply to the Letter to the Editor “Importance of pain management in cancer patients and survivors” by K. Bhatt et al.
|
Di Maio, M. |
|
|
35 |
5 |
p. 475-476 |
artikel |
11 |
Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
|
Agostinetto, E. |
|
|
35 |
5 |
p. 409-411 |
artikel |
12 |
Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms
|
Brenner, H. |
|
|
35 |
5 |
p. 476-477 |
artikel |
13 |
Table of Contents
|
|
|
|
35 |
5 |
p. i-ii |
artikel |
14 |
The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer
|
Bertucci, F. |
|
|
35 |
5 |
p. 477-478 |
artikel |
15 |
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
|
Yu, H.A. |
|
|
35 |
5 |
p. 437-447 |
artikel |
16 |
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
|
Olmos, D. |
|
|
35 |
5 |
p. 458-472 |
artikel |